Chalice Brands Past Earnings Performance
Past criteria checks 0/6
Chalice Brands has been growing earnings at an average annual rate of 10.1%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 22.3% per year.
Key information
10.1%
Earnings growth rate
49.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 22.3% |
| Return on equity | -34.3% |
| Net Margin | -22.2% |
| Last Earnings Update | 30 Sep 2021 |
Recent past performance updates
Revenue & Expenses Breakdown
How Chalice Brands makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 21 | 26 | -6 | 12 | 0 |
| 30 Jun 21 | 24 | -9 | 11 | 0 |
| 31 Mar 21 | 23 | -12 | 11 | 0 |
| 31 Dec 20 | 22 | -10 | 11 | 0 |
| 30 Sep 20 | 20 | -31 | 13 | 0 |
| 30 Jun 20 | 18 | -32 | 13 | 0 |
| 31 Mar 20 | 16 | -32 | 13 | 0 |
| 31 Dec 19 | 16 | -33 | 14 | 0 |
| 30 Sep 19 | 15 | -19 | 17 | 0 |
| 30 Jun 19 | 16 | -22 | 18 | 0 |
| 31 Mar 19 | 15 | -15 | 21 | 0 |
| 31 Dec 18 | 15 | -4 | 20 | 0 |
| 30 Sep 18 | 16 | -43 | 14 | 0 |
| 30 Jun 18 | 14 | -41 | 14 | 0 |
| 31 Mar 18 | 12 | -46 | 12 | 0 |
| 31 Dec 17 | 12 | -56 | 10 | 0 |
| 30 Sep 17 | 8 | -25 | 11 | 0 |
| 30 Jun 17 | 7 | -24 | 8 | 0 |
| 31 Mar 17 | 8 | -23 | 9 | 0 |
| 31 Dec 16 | 8 | -21 | 10 | 0 |
| 30 Sep 16 | 10 | -4 | 11 | 0 |
| 30 Jun 16 | 10 | -5 | 14 | 0 |
| 31 Mar 16 | 11 | -8 | 14 | 1 |
| 31 Dec 15 | 10 | -17 | 12 | 0 |
| 30 Sep 15 | 9 | -20 | 12 | 0 |
Quality Earnings: CHAL is currently unprofitable.
Growing Profit Margin: CHAL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CHAL is unprofitable, but has reduced losses over the past 5 years at a rate of 10.1% per year.
Accelerating Growth: Unable to compare CHAL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CHAL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Return on Equity
High ROE: CHAL has a negative Return on Equity (-34.31%), as it is currently unprofitable.